Biogen Pharmachem Industries L (BIOGEN.BO) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+160.5%

₹0.65

vs ₹0.25 price

Levered DCF

₹0.03

After debt service

Piotroski score

4 / 9

Average

Altman Z-score

49.33

Safe zone

Rating

D+

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	59.3×	-186.67×	31.85×	102.86×	-5,467.72×	-29.27×	-400×	-13,244.1×
P/B	0.51×	0.6×	1.09×	0.86×	0.87×	0.87×	0.84×	0.82×
P/S	19.93×	-153.42×	38.31×	51.47×	21.73×	3,247.41×	-187,949.66×	49.47×
EV / EBITDA	52.94×	-187.1×	31.86×	102.85×	-5,575.22×	-29.34×	-405.24×	-13,604.14×
Gross margin	84.7%	150.9%	94.1%	51.3%	3.9%	-10229.0%	31362.7%	4.2%
Operating margin	37.4%	81.9%	71.9%	49.9%	-0.5%	-11079.8%	46678.8%	-0.4%
Net margin	33.6%	81.9%	120.2%	49.9%	-0.4%	-11080.2%	46678.7%	-0.4%
Current ratio	309.8×	29.51×	0.3×	0.65×	2.37×	23.64×	76.11×	33.36×
Debt / equity	0×	0×	0×	0×	0×	0×	0.01×	0.01×
Interest coverage	0×	0×	0×	4,556×	-62.26×	-34,255.66×	0×	-73.22×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	0.9%	-0.3%	3.4%	0.8%	-0.0%	-3.0%	-0.2%	-0.0%
Return on invested capital	0.9%	-0.3%	2.0%	0.8%	-0.0%	-3.0%	-0.2%	-0.0%
Return on assets	0.9%	-0.3%	3.4%	0.8%	-0.0%	-3.0%	-0.2%	-0.0%
Free cash flow yield	3.1%	-2.0%	3.2%	3.6%	3.0%	8.4%	-2.6%	0.2%
Earnings yield	1.7%	-0.5%	3.1%	1.0%	-0.0%	-3.4%	-0.2%	-0.0%
Enterprise value	₹506.5M	₹547.6M	₹615.1M	₹468.6M	₹469M	₹470.4M	₹472.9M	₹476.1M
Net debt / EBITDA	-0.34×	0.19×	-0.01×	-0.28×	9.88×	-0.03×	-2.59×	-179.17×
Cash conversion cycle (days)	9,436	-75	12	18,330	8,089	253	-72,737,564	-2,757